Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS

This monocentric prospective study of patient suffering from Amyotrophic lateral sclerosis (ALS) aims to evaluate the prognosis and diagnostic potential of both Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in serum and CSF. Candidate markers levels were measured using multiplex method in serum of 60 ALS patients, 94 healthy controls of 43 patients suffering from Inflammatory Peripheral Neuropathies (IPN). A comparative CSF analysis was performed for 20 ALS and 17 IPN patients. Among the altered biomarkers, CSF Nf-L level remains the best marker of ALS severity, while serum levels correlate strongly with disease progression. The combination of Nf-L and ICAM-1 concentrations in the CSF and IFN-gamma concentration in the serum differentiate ALS patients from IPN patients with improved sensibility and specificity relative to individual biomarkers. A cutoff value of 0.49 for the fitted values of these 3 biomarkers discriminate ALS from IPN patients with a specificity of 100% (78.20-100%) and a sensibility of 85.71% (57.19-98.22%) with an AUC of 0.99 +/- 0.01. The measure of Nf-L and neuroinflammatory biomarkers in CSF and serum can be useful biomarkers panel in the differential diagnosis of ALS.

Automated summary

This study evaluates the prognostic and diagnostic potential of Neurofilament-Light (Nf-L) and neuroinflammatory biomarkers in ALS patients. The combination of Nf-L, ICAM-1, and IFN-gamma levels show promise in differentiating ALS patients from those with Inflammatory Peripheral Neuropathies (IPN) with improved sensitivity and specificity. The measurement of these biomarkers in CSF and serum could be useful in the differential diagnosis of ALS.